Tscan therapeutics announces first patient dosed in phase 1 umbrella clinical trial evaluating tsc-100 and tsc-101 for the treatment of hematologic malignancies

Patient treated with tsc-101, the first clinical cell therapy product targeting minor histocompatibility antigen ha-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation patient treated with tsc-101, the first clinical cell therapy product targeting minor histocompatibility antigen ha-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation
TCRX Ratings Summary
TCRX Quant Ranking